Drug Profile


Alternative Names: DDFPe; Dodecafluoropentane; NVX-108; Perfluoropentane; PFP

Latest Information Update: 02 Sep 2016

Price : $50

At a glance

  • Originator NuvOx Pharma
  • Class Diagnostic agents; Fluorocarbons; Radiation-sensitising agents; Radiosensitisers; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma

Most Recent Events

  • 02 Sep 2016 Phase-II clinical trials in Glioblastoma (Combination therapy, Newly diagnosed) in Australia (IV)
  • 02 Dec 2015 Perflenapent receives Orphan Drug status for Glioblastoma in USA
  • 01 May 2014 Phase-I/II clinical trials in Glioblastoma (combination therapy, newly diagnosed) in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top